Successful erlotinib rechallenge after both gefitinib‐ and erlotinib‐induced interstitial lung diseases

Respirology Case Reports

Nobuhito Arakawa²  Akihiro Tsujita²  Noriko Saito¹  Shigemi Ishikawa¹ 

[1] Department of Thoracic Surgery, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan;Department of Pulmonary Medicine, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan

关键词: Epidermal growth factor receptor tyrosine kinase inhibitor;    erlotinib;    gefiitinib;    glucocorticoid;    interstitial lung disease;   

DOI  :  10.1002/rcr2.12

来源: Wiley

【 摘 要 】

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors, gefitnib and erlotinib, are effective for advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutation. However, interstitial lung disease induced by these drugs is sometimes fatal, and discontinuation of the medication is the principle approach once this occurs. There are, however, some reports of cases in which rechallenge of gefitinib or erlotinib was successful, and it remains unclear when or how rechallenge should be attempted. We report the first successful case of erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases. Our case suggests that, in interstitial lung disease induced by an epidermal growth factor receptor tyrosine kinase inhibitor, rechallenge with concurrent glucocorticoid administration and gradual increase of dosage could be a clinical option if imaging does not show a diffuse alveolar damage pattern, and if no alternative therapy is available.

【 授权许可】

CC BY-NC-ND   
© 2013 The Authors. Respirology Case Reports published by John Wiley & Sons Ltd on behalf of The Asian Pacific Society of Respirology.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.